Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience
Naimisha Marneni(Vanderbilt University Medical Center), Muhamed Baljević(Vanderbilt University Medical Center), Shakthi Bhaskar(Vanderbilt University Medical Center), Jordan Berlin(Dana-Farber Cancer Institute), Olalekan O. Oluwole(Vanderbilt University), Vivek Patel(Vanderbilt University Medical Center), Adetola A. Kassim(Vanderbilt University), Sanjay Mohan(Breast Cancer Research Foundation), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Ashwin Kishtagari(Memorial Sloan Kettering Cancer Center), David Morgan(Vanderbilt University Medical Center), Salyka Sengsayadeth(VA Tennessee Valley Healthcare System), Bipin N. Savani(Vanderbilt University Medical Center), Eden Biltibo(Vanderbilt University Medical Center), Jill Gilbert(Cancer Clinic), Reena Jayani(Vanderbilt University Medical Center)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k